F3Logic’s BioMarin Pharmaceuticals BMRN Stock Holding History

F3Logic’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-300	Closed	-$22.8K	–	245
2020 Q3	$22.8K	Buy	+300	New	+$30.4K	0.58%	49

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

F3Logic's BMRN Position: Q4 2020 in Review

F3Logic sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2020, closing a stake of 300 shares — an estimated $22.8K sold.

F3Logic first reported a position in BMRN in Q3 2020 and held it in 1 quarter. The position peaked at $22.8K in Q3 2020. 537 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

F3Logic reported no remaining BioMarin Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
F3Logic sold 300 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $22.8K.
F3Logic first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 1 quarter.
F3Logic's BioMarin Pharmaceuticals position peaked at $22.8K in Q3 2020.
537 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on F3Logic's 13F filing for Q4 2020, filed 12 Feb 2021.